logo
Plus   Neg
Share
Email

Haemonetics Boosts FY20 Adj. EPS Outlook - Quick Facts

While reporting financial results for the third quarter on Tuesday, healthcare company Haemonetics Corp. (HAE) again raised its adjusted earnings guidance for the full-year 2020, while reaffirming annual revenue growth outlook.

For fiscal 2020, the company raised its adjusted earnings guidance to a range of $3.30 to $3.40 per share from the prior forecast range of $3.10 to $3.20 per share, while continuing to project annual revenue growth of 3 to 5 percent and organic revenue growth of 6 to 8 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $3.18 per share on revenue growth of 3.8 percent to $1.0 billion for the year. Analysts' estimates typically exclude special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Guitar Center Inc., a retailer of musical instruments, lessons, repairs and rentals, has filed for Chapter 11 bankruptcy reorganization, aiming to significantly reduce its debt and continue its business amid ongoing struggles following the coronavirus pandemic. The company, which operates nearly 300 stores across the U.S., expects to complete the process before the end of this year. Amazon is offering new "Spoiler Free" ways to keep gifts a surprise, as well as to track, receive and pick up orders this holiday season. According to the company, the new features would help customers to face the challenge of keeping those special gifts under wraps as many families are opting to stay home amid the coronavirus pandemic. AstraZeneca Plc and Oxford University's coronavirus vaccine candidate AZD1222 is found to be 70 percent effective on average against Covid-19, according to the British pharmaceutical giant. AstraZeneca plans to immediately prepare regulatory submission of the data to worldwide authorities for conditional or early approval. The company will also ask for an Emergency Use Listing from the WHO.
RELATED NEWS
Follow RTT